Ketamine and Esketamine in Treatment-Resistant Depression: Bridging Rapid Response, Durability and Safety, and Practical Management

Treatment-resistant depression, most often defined as inadequate response to at least two antidepressants, is common and costly, and intravenous racemic ketamine and intranasal esketamine are described as rapid-acting, non-monoaminergic options. This narrative review asks how fast and large the response is, how long it lasts, what the safety burden is and how the agents compare with electroconvulsive therapy and augmentation; it describes Saudi and Gulf data and proposes a practical approach. We searched PubMed in November 2026 and screened titles, so this is a targeted selection and not a systematic search. Randomized evidence suggests a rapid antidepressant effect of both agents, but its size differs: indirect syntheses favored racemic ketamine, not always significantly, and two of the three short-term phase 3 esketamine trials, each adding a newly started oral antidepressant, did not meet their primary endpoint. Durability rests on one randomized-withdrawal trial of esketamine in responders and on open-label studies without a control group; controlled evidence for maintenance intravenous ketamine is limited. Acute adverse effects include transient dissociation, raised blood pressure and sedation; evidence of bladder toxicity in therapeutic use is not convincing, and sources differ on misuse. Ketamine was non-inferior to electroconvulsive therapy in a large open-label trial of patients without psychosis who were referred for it, and inferior in a trial of hospitalized patients; esketamine outperformed extended-release quetiapine in an open-label trial. The only Gulf clinical outcome data retrieved are an uncontrolled series of twenty patients. We close with a stepwise approach labeled by type of evidence.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-22
DOI
https://doi.org/10.5281/zenodo.24430893
Primary Topic
Treatment of Major Depression
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Ketamine and Esketamine in Treatment-Resistant Depression: Bridging Rapid Response, Durability and Safety, and Practical Management

Salman Mashary Alharbi, Yusuf Mohammad Alkahtani
Zenodo (CERN European Organization for Nuclear Research)
Treatment of Major Depression
preprint

Ketamine and Esketamine in Treatment-Resistant Depression: Bridging Rapid Response, Durability and Safety, and Practical Management

Salman Mashary Alharbi, Yusuf Mohammad Alkahtani
preprint en

Abstract

Treatment-resistant depression, most often defined as inadequate response to at least two antidepressants, is common and costly, and intravenous racemic ketamine and intranasal esketamine are described as rapid-acting, non-monoaminergic options. This narrative review asks how fast and large the response is, how long it lasts, what the safety burden is and how the agents compare with electroconvulsive therapy and augmentation; it describes Saudi and Gulf data and proposes a practical approach. We searched PubMed in November 2026 and screened titles, so this is a targeted selection and not a systematic search. Randomized evidence suggests a rapid antidepressant effect of both agents, but its size differs: indirect syntheses favored racemic ketamine, not always significantly, and two of the three short-term phase 3 esketamine trials, each adding a newly started oral antidepressant, did not meet their primary endpoint. Durability rests on one randomized-withdrawal trial of esketamine in responders and on open-label studies without a control group; controlled evidence for maintenance intravenous ketamine is limited. Acute adverse effects include transient dissociation, raised blood pressure and sedation; evidence of bladder toxicity in therapeutic use is not convincing, and sources differ on misuse. Ketamine was non-inferior to electroconvulsive therapy in a large open-label trial of patients without psychosis who were referred for it, and inferior in a trial of hospitalized patients; esketamine outperformed extended-release quetiapine in an open-label trial. The only Gulf clinical outcome data retrieved are an uncontrolled series of twenty patients. We close with a stepwise approach labeled by type of evidence.

Zenodo (CERN European Organization for Nuclear Research)
King Saud University (SA)
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Ketamine and Esketamine in Treatment-Resistant Depression: Bridging Rapid Response, Durability and Safety, and Practical Management — Salman Mashary Alharbi, Yusuf Mohammad Alkahtani · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS